Deals roundup: Warburg will pay cash $239 million to acquire Lifecore Biomedical Jan. 16, 2008 By Amanda Pedersen
Alfacell Deals U.S. Rights for Onconase to Strativa Jan. 16, 2008 By Trista Morrison Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million. (BioWorld Today)Read More
Public firms vie for interest – and investor dollars – ‘08 and beyond Jan. 16, 2008 By Holland Johnson
RSS